AR Inhibition Achieves Responses in AR+ Triple-Negative Breast Cancer
- PMID: 29439153
- DOI: 10.1158/2159-8290.CD-RW2018-022
AR Inhibition Achieves Responses in AR+ Triple-Negative Breast Cancer
Abstract
The AR inhibitor enzalutamide achieved responses in patients with advanced TNBC in a phase II trial.
©2018 American Association for Cancer Research.
Comment on
-
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373071 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials